IL-3 is a glycoprotein cytokine involved in the hematopoietic response to infectious, immunologic, and inflammatory stimuli. In addition, clinical administration of recombinant IL-3 augments recovery in states of natural and treatment-related marrow failure. IL-3 acts by binding to high affinity cell surface receptors present on hematopoietic cells. To determine the site(s) at which IL-3 binds to its receptor, we analyzed a series of interspecies chimera of the growth factor for species-specific receptor binding and biological activity. The results suggest that IL-3 binds to its receptor and triggers a proliferative stimulus through two noncontiguous helical domains located near the amino terminus and the carboxy terminus of the molecule. To corroborate these findings, we have also mapped the binding epitopes of 10 mAb of human or murine IL-3, and have defined four distinct epitopes. Two of these epitopes comprise the amino-terminal receptor binding domain. A third epitope corresponds to the carboxy-terminal receptor interactive domain, and the fourth epitope, apparently not involved in the interaction of IL-3 and its receptor, lies between these sites. And on the basis of sandwich immunoassays using pairs ofthese mAbs, the two receptor interactive regions appear to reside in close juxtaposition in the tertiary structure of the molecule. These results provide a correlation of the structure-function relationships of IL-3 that should prove useful in evaluating the details of IL-3-IL-3 receptor interaction and in the rational design of clinically useful derivatives of this growth factor. (J.
Introduction
IL-3 or multi-colony-stimulating factor (CSF)' is an acidic glycoprotein involved in the survival and self-renewal ofhematopoietic stem cells, the proliferation and differentiation of 1 . Abbreviations used in this paper: FICA, Freund's incomplete adjuvant; GM-CSF, granulocyte-macrophage colony-stimulating factor; NHIA, N-hydroxysuccinimide ester of iodoacetic acid. committed progenitors and in the functional activation of mature leukocytes (1) (2) (3) . In this way, IL-3 is thought to be involved in the host response to noxious stimuli. In addition, recent studies have implicated in the pathogenesis of asthma and hypersensitivity (3) (4) (5) , and in murine and human leukemia (6) (7) (8) .
IL-3 acts by binding to high affinity cell surface receptors, which are normally present only on cells of hematopoietic lineage (8, 9) . Recently, low affinity receptors for human and murine IL-3 were cloned (10, 1 1). On the basis of conserved cysteine residues and a five amino acid WSXWS region, the IL-3 receptor was thought to be a member of a growing family of polypeptides that includes the receptors for IL-2, IL-4, IL-5, IL-6, IL-7, granulocyte-macrophage (GM)-CSF, granulocyte CSF, and erythropoietin (12) . Based on this homology and receptor cross-linking data, it was proposed that the IL-3 receptor, like the IL-2 and IL-6 receptors, is composed ofat least two subunits ( 12, 13) . This supposition was recently confirmed by Kitamura et al., who demonstrated that a non-ligand-binding subunit ofthe human GM-CSF receptor ( 14) also induces high affinity IL-3 binding when expressed with the low affinity IL-3 receptor ( 11) . This finding has also provided potential mechanisms to explain the reciprocal competition displayed by IL-3 and GM-CSF for binding to cells that bear receptors for both of these cytokines (13, 15, 16) .
Despite its pivotal role in hematopoiesis, little is known of the structural features of IL-3 that are responsible for receptor binding and biological activity. Initial studies using truncated synthetic polypeptides of murine IL-3 suggested that the first disulfide bond and the amino-terminal half ofthe molecule are responsible for biological activity (17, 18) . Recently, two groups have reported on the binding sites ofneutralizing mAbs of human IL-3 (19, 20) . Together, 13 mAbs were mapped to residues between Gln29 and Glu50, helping to localize the site of this amino-terminal domain of biological activity. One study has reported on carboxy-terminal truncation mutants of human IL-3 (19) . Although the 10 carboxy-terminal residues were dispensable, the activities of more severe truncation mutants were reduced three to four orders ofmagnitude, making it likely that residues immediately upstream of this position are also involved in receptor interaction.
A number of additional strategies have been used to map the receptor-interactive residues ofbiologically active polypeptides. Most depend on the activities of internally deleted polypeptides. However, these methods cannot distinguish between loss of activity caused by alterations in secondary or tertiary structure and that caused by loss of a receptor interactive site.
Recently, we developed a strategy of substitution mutagenesis based on the structural similarity but biological distinctiveness of the human and murine analogs of a hematopoietic growth factor, GM-CSF (21 ) . By generating cross-species chimera and testing them for species specific function, receptor-interactive residues were identified. Human (or gibbon) and murine IL-3 are also species-specific: They do not stimulate the growth of progenitor cells or the function of mature cells from the alternate species, and they do not cross-react at the receptor level. Monoclonal antibodies to human or murine IL-3 also react in a species specific fashion. To further explore the structure-function relationships of IL-3, we used this species specificity to map the sites of receptor binding and biological activity of primate and murine IL-3. Using this approach, two nonlinear sites ofIL-3-IL-3 receptor interaction were identified. The first site appears to be sufficient for receptor binding, but inadequate to transmit a proliferative stimulus. The second site is necessary for biological activity. We also show that these two sites correlate with the binding epitopes of several neutralizing mAbs of IL-3, but not with nonneutralizing mAb epitopes. Together, these findings support the hypothesis that the receptor binding domain of IL-3 is composed of at least two elements from distinct regions of the molecule and begin to provide an understanding of the events that lead to a proliferative stimulus in hematopoiesis.
Methods
Generation of chimeric IL-3 cDNA expression vectors. Full-length cDNA clones for gibbon IL-3 (Dr. Steve Clark, Genetics Institute, Cambridge, MA) and murine IL-3 (Dr. Frank Lee, DNAX Institute, Palo Alto, CA) were subjected to site-directed mutagenesis, as previously described (21 ) , to introduce useful restriction sites or to directly alter the coding sequences (Fig. 1) . Recombinant hybrid cDNA expression vectors were produced by ligating restriction fragments of the mutant gibbon or murine IL-3 cDNA into the mammalian cell expression vector pDX (22) by standard techniques. Each mutation and ligation was verified by single-stranded or plasmid DNA sequencing using the dideoxynucleotide chain termination method (23) .
Expression ofchimeric IL-3 molecules. BHK cells were obtained from American Type Culture Collection (Rockville, MD) and maintained in Dulbecco's MEM supplemented with 5% FCS and antibiotics. Cells were transfected with the chimeric IL-3 expression vectors and a dihydrofolate reductase (DHFR) expression vector (24) by the calcium phosphate method when 30% confluent, as previously described (2 1). After 3 d, the cells were divided and cultured in 250 nM methotrexate. Individual colonies were selected, expanded, and assayed for species-specific IL-3 mRNA expression by slot blot analysis using full-length cDNA clones for gibbon or murine IL-3 labeled by random priming (Multiprime DNA Labeling System; Amersham Corp., Arlington Heights, IL). Cell lines expressing high levels of IL-3-specific RNA were then selected for analysis. To generate biosynthetically "S-labeled IL-3 molecules, the cell lines expressing chimeric proteins were grown in DMEM devoid of cysteine and methionine, and supplemented with 2% dialyzed FCS, antibiotics, and 50
,gCi/ml "5S-Cys + Met (Express; New England Nuclear, Boston, MA).
The medium was then harvested after 24-36 h.
Quantitative Western blot analysis. The level ofspecific protein was determined by quantitative Western blotting (21, 22) . Aliquots ofconditioned culture medium from cell lines expressing chimeric IL-3 proteins were denatured, size fractionated through 12% polyacrylamide gels, transferred to nitrocellulose, and probed with a 1:50 dilution of a rat antiserum raised against a synthetic peptide composed of the 16 amino-terminal residues of human IL-3 (peptide 4, reference 25). Since this antiserum reacts equally well with IL-3 derived from bacterial or mammalian cell expression systems, human IL-3 purified from recombinant Escherichia coli served as a quantitative control. An 125I goat anti-rat Ig antiserum was used to detect immune complexes on the blot. After autoradiography, blots were analyzed by phosphorimaging (Molecular Dynamics, Sunnyvale, CA) to quantitate the amount of '25I-detecting reagent present.
Hematopoietic progenitor cell assays. Human marrow cells were obtained from consenting healthy adult volunteers, under a protocol approved by the University of Washington (Seattle, WA). Nonadherent human marrow mononuclear cells were used to assay chimeric IL-3 molecules for their ability to stimulate the growth of granulocytemacrophage colony-forming cells, as previously described (21) . The murine IL-3-dependent cell line FDCP1 was obtained from American Type Cuture Collection and was maintained in DMEM with 10% FCS and 50 U/ml murine GM-CSF. The FDCP1 cells were used to assess the ability of IL-3 molecules to stimulate murine colony growth, and for murine IL-3 receptor binding assays, as described below. The colony-forming capacity of FDCP1 cells has been shown to correlate precisely with the ability of CSF to stimulate progenitor cell growth from murine marrow cells (26) . These results were also confirmed using murine marrow cells, as previously described (21) .
Receptor binding assays. The human erythroleukemia cell line OCIMI (27) , and the radiologic specific activity ofthe labeled IL-3 protein was determined by self displacement analysis (30) . The amount of 3"S-IL-3 produced in a typical 200 Mul reticulocyte lysate reaction was 20 ng. The 35S-IL-3 was then used in a receptor binding assay. OCIM 1 cells were incubated with varying quantities of 3"S-gibbon IL-3 (7-330 pM) with or without a 1,000-fold excess of unlabeled IL-3 in binding buffer for 1 h at 37°C, as described above. All receptor binding data were analyzed using the LIGAND program (31) .
Generation ofrat antipeptide IL-3 (human and mouse) monoclonal antibodies. A synthetic oligopeptide [(C) PNLEAFNRAVKSLQNA-SAI ] corresponding to residues 56-74 ofthe human IL-3 molecule, was obtained commercially (Applied Biosystems Inc., Foster City, CA).
The terminal thiol was used to covalently couple the peptide to sperm whale myoglobin (Sigma Chemical Co., St. Louis, MO), using the heterobifunctional crosslinking reagent N-hydroxysuccinimide ester of iodoacetic acid (NHIA) (32) . Myoglobin sulfhydryl groups were first blocked by reacting 10 ml of 5 mg/ml myoglobin in 0.1 M sodium bicarbonate with 1 ml of0.12 M iodoacetamide (Sigma Chemical Co.) 1880 for 1 h at room temperature followed by overnight dialysis against 0.1 M bicarbonate.
A 5 mg/ml solution ofpeptide was prepared in 2 ml of0.1 M DTT, 50 mM Tris, 2.5 mM EDTA, pH 8, and incubated overnight at 370C. The reduced peptide was applied to a 1.5 X 26.5 cm gel-filtration column (GF 05; LKB Instruments, Inc., Gaithersburg, MD), and was eluted with 15 mM acetic acid, 5 mM fl-mercaptoethanol. Material eluting in the void volume was pooled and lyophilized. The carboxyamidated myoglobin recovered from dialysis was iodoacetylated by reaction with 0.38 ml of 5 mg/ml NHIA in tetrahydrofuran for 30 min at room temperature with vigorous stirring, followed by dialysis against PBS. The lyophilized peptide was resuspended in 5 ml of 10 mM Na2B4O7, 0.29 M NaCI, 1 mM EDTA, pH 8.5 (which had been N2-purged for 30 min, followed by addition of 178 mg/ml ascorbate), and mixed with an equal volume of iodoacetylated myoglobin recovered from dialysis. The conjugation reaction was carried out at room temperature overnight.
A Lewis rat was immunized intraperitoneally with 100 Ag of peptide-myoglobin conjugate in CFA. The animal was boosted three times with the same peptide conjugate in Freund's incomplete adjuvant (FICA), and splenocytes were fused with P3X63-AG8.653 myeloma cells (American Type Culture Collection) using 50% polyethylene glycol (33) . This fusion resulted in the 8A5 mAb.
The 10F4 rat anti-mouse IL-3 peptide antibody was prepared in a similar fashion using an oligopeptide [(C) VESQGEVDPEDRYVI]-ovalbumin conjugate comprising residues 56-70 ofmature mouse IL-3 (the analogous residues to those used for human IL-3). This antibody has been previously shown to work in Western blotting, as well as in an indirect ELISA of mouse IL-3 (34, 35).
Generation ofrat anti-IL-3 (human and mouse) monoclonal antibodies. Two series of fusions with different immunogen forms were carried out to obtain the neutralizing rat anti-human IL-3 antibodies used in this study. In the first fusion, male Lewis rats were immunized with 50 ug i.p. yeast expressed-recombinant IL-3 in CFA. Splenocyte fusion with the P3X63-AG8.653 myeloma was carried out 4 d after the fourth boost. Anti-IL-3 antibody secreting hybridoma were selected on the basis ofscreening by indirect ELISA on IL-3-coated polyvinylchloride microtiter plates, as well as neutralization ofIL-3-induced proliferation of the KG-I (American Type Culture Collection) myelomonocyte cell line assessed colorimetrically with [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] by the method of Mosmann (36) . This fusion produced the IF9 and the 6G8 antibodies. A subsequent fusion was carried out using glutaraldehyde crosslinked (37) yeast-expressed IL-3 to produce antibodies recognizing different epitopes, as well as more potent neutralizing activity. Yeast-expressed IL-3 was concentrated to 0.2 mM by Centricon 10 ultrafiltration in PBS, 0.01% Tween 20 (Sigma Chemical Co.). Glutaraldehyde (Sigma Chemical Co.) was added to a final concentration of 2 mM ( 10:1 M glutaraldehyde/cytokine). The reaction was incubated for I h at room temperature, then quenched with L-lysine (final concentration 0.1 M) for an additional hour at room temperature and stored at 4°C. Male Lewis rats were immunized intraperitoneally with cross-linked IL-3 in CFA. Animals were boosted twice with cross-linked IL-3 in FICA, and then with IL-3 in PBS before splenocyte fusion. Anti-IL-3 antibody-secreting hybridoma were selected based on inhibition of IL-3-dependent proliferation of the multifactor TF-l erythroleukemic cell (38) . This fusion produced the 3G I 1 antibody.
The development and characterization ofthe neutralizing rat antimouse IL-3 monoclonal antibodies 8F8, 19B3, and 43D I have been previously described (33) . These mAbs exclusively recognize human (and gibbon) or murine IL-3, including that made in E. coli and Saccharomyces cerevisiae expression systems.
Generation ofmouse anti-human IL-3 monoclonal antibodies. Five BALB/CJ-Bailey mice (Jackson Laboratory, Bar Harbor, ME) were immunized with recombinant human IL-3 (rhIL-3) by 4 Binding characteristics ofanti-IL-3 mAbs. To determine the capacity of the anti-human IL-3 mAbs to bind to denatured protein, Western blots were prepared using recombinant human IL-3 produced in E. coli. After transfer, the blots were denatured and reduced with 20% methanol and 30 mM fl-mercaptoethanol at 80'C for 30 min and then iodoacetylated with 30 mM iodoacetic acid in the dark at 20'C. This step was included to make certain that the transferred proteins were fully denatured before detection with each mAb.
Immunoprecipitation of metabolically labeled IL-3 proteins. 1 ml of 35-Met/Cys-labeled conditioned culture medium was mixed with 10 Mug of affinity-purified antibody or 100 Ml of monoclonal antibody ascites fluid (8A5 and I 1F4) and incubated for 4-16 h at 4°C. For the rat mAbs, 20Mug ofanti-rat Ig (Cappel Laboratories, Cochranville, PA) was added for 3 h at 4°C. For the murine mAb, rabbit anti-murine Ig was used, and both sets of immune complexes were precipitated with Staph A (Pansorbin; Calbiochem Corp., La Jolla, CA) (39) . Immunoprecipitates were size fractionated on 12% NaDodSO4 polyacrylamide gels, the gels were fixed, soaked in Amplify solution (Amersham Corp.), dried, and exposed to film for 2-20 d.
Identifcation of antibody pairs recognizing spatially distinct epitopes on human IL-3. An immunoenzymetric assay format was used to identify antibody pairs recognizing spatially distinct epitopes on the IL-3 molecule. Polyvinylchloride "U" bottom microtiter plates were coated with 10 Mg/ml in PBS for 2 h at 37°C with various rat monoclonal anti-IL-3 antibodies. These were produced in vitro in HB102 medium and purified by 66% saturated ammonium sulfate precipitation and AcA44 gel filtration chromatography, essentially as described (40) . Plates were washed (three cycles) between all steps with salineTween 20. Serial dilutions of IL-3 (a 100-Ml vol in RPMI, 15% fetal bovine serum containing 40 ng-5 pg/ml) were incubated for 2 h at room temperature. Nitro-iodophenyl (NIP)-conjugated anti-IL-3 mAbs were prepared by reacting I mg/ml IgG in PBS with 10 Ml NHIA (5 mg/ml in DMSO) for I h at room temperature, followed by overnight dialysis against PBS. NIP-labeled antibodies (100 Ml of 1 The biologic activity ofchimeric IL-3 proteins. Serial dilutions of the chimeric IL-3-conditioned culture media were assayed for biologic activity in colony-forming assays using human or murine marrow cells (Table I) . Together with the quantitative analysis from the Western blot experiments, the specific activities of each chimeric growth factor (relative to native human or murine IL-3) were determined. Beginning from the amino terminus, chimeric protein gm 3 was nearly fully active using murine assays. As expected from the speciesspecificity of gibbon and murine IL-3, gm 3 failed to stimulate human progenitors to form hematopoietic colonies. Because of the sequence homology between gibbon and murine IL-3 in residues 16-22, chimeric protein gm 2 represents a five-amino acid substitution mutant of gm 3 (L15 to V14 and SIVK22 to NMID21). The presence of these changes alone resulted in the nearly complete inactivation of chimeric gm 2 in the murine marrow cell proliferation assays (Table I) .
To further investigate the importance of residues in this region, an additional double substitution mutant termed 2207 was analyzed. As shown in Fig. 1 tive protein (Fig. 2) . In contrast, gm 9, which differs from gm 1 at only six positions (between residues F107 through EII9), was nearly fully active using human marrow progenitor cells (Table  I) Receptor binding activity ofthe chimericproteins. Receptor binding assays were performed using the human erythroleukemia cell line OCIMl and the murine factor-dependent cell line FDCP1. These cells display high affinity receptors for human and murine IL-3, respectively. As shown in Table II , chimeric proteins that contain at least the amino-terminal 45 residues of gibbon IL-3 were able to compete with human IL-3 for binding to the IL-3 receptor on OCIM 1 cells. Chimeric molecules that contain at least the 124 carboxy-terminal residues of the murine protein (residues 16-140) could compete for binding of 1231-murine IL-3 to FDCP1 cells. These data suggest that some of the same residues identified by the colony-forming assays were required for receptor binding. In addition, these data imply that molecules (e.g., gm 6) that fail to stimulate a biologic response are capable, albeit with reduced affinity, ofbinding to the IL-3 receptor. To be certain that these findings were not caused by differences between the human and gibbon growth factors, we adapted an in vitro translation system to produce radioactively pure gibbon IL-3. Metabolically "S-labeled proteins were then tested in the receptor binding assay. Using 3S-gibbon IL-3, OCIM1 cells were found to display 470 receptors per cell with a Kd of 52 pM (Fig. 3) . These results for receptor binding avidity compare favorably with that using 1251-human IL-3 (170 receptors per cell, Kd 63 pM) and suggest that the gibbon and human molecules interact identically with the human IL-3 receptor. The discrepancy between receptor number identified by human and gibbon IL-3 likely relates to Mappingthebindingepitopes ofanti-IL-3 monoclonal antibodies. A series of five distinct anti-human IL-3 and three distinct anti-murine IL-3 mAbs were raised against the recombinant proteins. In addition, antipeptide mAbs raised against residues 56-74 of human IL-3 and against residues 56-70 of murine IL-3 were also available for analysis. The capacity of these mAbs to recognize denatured human or murine IL-3 in a Western blot format is shown in Fig. 4 . To be certain that the IL-3 proteins were completely denatured on the nitrocellulose, the blots were treated with NaDodSO4 and f,-mercaptoethanol and were acetylated after transfer. The strong signal for each mAb strongly suggests that each antibody recognizes a discrete, short linear array of IL-3-specific amino acids. Next, several of the mAbs were used to detect the chimeric IL-3 proteins by Western blot analysis. The results from two informative experiments are shown (Fig. 4, B (Table   III) , this site likely comprises at least part ofthe receptor binding domain of the growth factor. From similar considerations, the differential reaction of the anti-murine IL-3 mAb 43D1 1 with chimera gm 2 and gm 6 suggests that this antibody binds to murine IL-3 between residues Val2l (corresponding to human IL-3 Ile20) and Pro4o (corresponding to human IL-3 Gln45). Furthermore, as 43D1 1 neutralizes the biological activity of murine IL-3 (33) , this region is also involved in the interaction between IL-3 and its receptor.
To expand upon the Western blotting results and to be certain that the mAbs used in this study recognize IL-3 under physiologic conditions, we next prepared "S-labeled IL-3 proteins and performed immunoprecipitation analyses. Fig. 5 shows the results obtained using several ofthe anti-human and anti-murine IL-3 mAbs. Based on their precipitation of chimera gm 6 but failure to recognize gm 2, mAbs 6G8, lF9, and 2.6.23 were mapped to residues between Asp21 and Gin45. Thus, these antibodies recognize an epitope quite similar to the anti-murine IL-3 mAb 43D1 1. Since 6G8, IF9, and 2.6.23 also block binding of human IL-3 to OCIM 1 cells (Table III) , these results also point to the importance of this region in the interaction between human IL-3 and its receptor. Like anti-human mAb 4.4.7, anti-murine mAbs 8F8 and 19B3 recognized residues between Leu15 (human VaI14) and Lys22 (human Asp21). Both of these mAbs neutralized murine IL-3 (33), again confirming the importance of this region for receptor binding and again, demonstrating the concordance of the structural organization of human and murine IL-3. A third, central epitope was defined by the antipeptide antibodies 8A5 and I0F4. These mAbs recognize human residues 56-74 and murine residues 56-70, and are bound to native IL-3, as judged by their ability to immunoprecipitate the mole- '25I-labeled human IL-3 (hIL3) was added to OCIM I cells in the presence of each of the anti-human IL-3 mAb. The percentage of competition compared to a 50-fold excess of unlabeled human IL-3 is reported. In this experiment, 55% of the bound cpm could be competed with the unlabeled IL-3, and the experiment has been repeated twice with similar results. mAb 2.1.3 was raised against human GM-CSF and used as a negative control.
cule from physiologic solution (Fig. 5) . However, they did not neutralize the biological activity of human or murine IL-3 (35) . Thus, these mAbs define a central domain not essential for the biological function of IL-3. The fourth epitope defined in this study includes human residues PheI07 through GluII9, and is recognized by the antihuman IL-3 mAb 3G (Fig. 5 C) . Again, as 3G recognized denatured IL-3 in a Western blot format (Fig. 4 A) , these residues likely encompass most, if not all of its binding epitope. And, as 3G blocks binding of human IL-3 to its receptor (Table III) , as does an Fab fragment derived from it (data not shown), this result also defines residues that interact with the IL-3 receptor. A summary of the mAb mapping studies using the interspecies chimera is presented in Fig. 6 . Cross-reactivity ofanti-IL-3 mAb. To confirm the assignment of epitope regions using the interspecies chimeric proteins, several pairs of mAbs were tested in an ELISA format. For the most part, pairs of mAbs that were assigned to nonoverlapping regions of IL-3 would simultaneously bind to IL-3 in this assay (e.g., 3Gl / lF9 pair, Fig. 7) . However, one unexpected finding was the failure of 6G8 and 3G to simultaneously bind to human IL-3. Two conclusions derive from these findings. First, although 6G8 and lF9 bind to the same panel of IL-3 chimera, they apparently recognize subtly different epitopes. And second, the failure of6G8 and 3Gl to simultaneously bind to IL-3 suggests that the epitopes for these two mAbs may reside in close juxtaposition in the tertiary structure of the molecule.
Secondary structural analysis ofIL-3. Finally, to begin to correlate the functional domains of IL-3 with its structure, a secondary structure prediction ofhuman IL-3 based on several different computer algorithms was performed and is shown in Fig. 8 . Taken together, these algorithms point to the presence of four helixes. Using the Chou and Fasman predictions, (that residues 17-29,41-51,57-78, and 103-125 ofhuman IL-3 are a helixes) and the algorithm ofEdmunson, the first and fourth predicted helixes are highly amphipathic; i.e., contain both hy- 1884 Kaushansky et al. drophobic and hydrophilic faces (Fig. 8, B and C) . Next, the sequences of human and murine IL-3 in these regions were compared. As shown, the human and murine IL-3 sequences differ primarily on the hydrophilic faces. Strong sequence conservation is present only for the (presumably) structurally important hydrophobic residues in these helixes. Of note, the two regions identified as critical for receptor binding, biological activity, and for the binding of neutralizing mAbs are located on the first and fourth predicted a helixes. (48) . In addition to 26% amino acid identity and 40% homology based on conservative substitutions, the biologically critical disulfide bond of IL-3 is conserved throughout evolution ( 18, 25 ) . Furthermore, Pakula and Sauer have recently shown that surface side chain changes have little impact on the tertiary structure ofpolypeptides (49) . Thus, the finding that nearly all ofthe amino acid changes between gibbon and murine IL-3 in the two regions found critical for biologic activity occur at the surface of the growth factor (Fig. 8) suggests that the tertiary conformation ofgibbon and murine IL-3 are quite similar and that the folded structure of the gibbon-murine hybrids used in this study approaches that of the native proteins.
In the amino-terminal region, murine IL-3 residues Leus through Lys22 (corresponding to gibbon residues Vall4 through Asp21) appear to be critical for colony-stimulating activity.
This was best exemplified by comparing the colony-stimulating activity ofmutants gm 3 and gm 2, which differ only in five positions (Leuls and Serj9 through Lys22. Furthermore, gibbon IL-3-specific residues in this region were required for binding to the human IL-3 receptor (gm 6 vs. gm 2, Table II ) and murine IL-3-specific amino acids were required for binding to the murine IL-3 receptor (gm 3 vs. gm 2). In addition, the F6b fragment of a mAb (termed 4.4.7) that blocked binding of human IL-3 to its receptor also bound to human IL-3 in this same region. Similar results were obtained for the anti-murine IL-3 mAbs 19B3 and 8F8. The mild reduction (sixfold) in the activity ofgm 3 compared to murine IL-3 suggest that the first 15 residues contribute in a minor way to full biological activity.
Additional residues immediately downstream ofthis region also appear to be involved in receptor binding. The anti-human IL-3 mAbs 6G8, 2.6.23, and IF9, and the anti-murine IL-3 mAb 43D1 1 recognize a closely contiguous epitope, located between human Asp21 and Gln45 (murine Lys22 and Pro4o). All of these mAbs block binding to the IL-3 receptor and neutralize the biological activity of the growth factor. In addition, together with two other reports ( 19, 20) (50, 51) . These antibodies failed to neutralize IL-3 bioactivity. Ziltener and colleagues have also described two mAbs that mapped very closely to the carboxy terminus of murine IL-3, residues Ser,30 through ArgI35 (52) . Neither of these mAbs neutralized the bioactivity of IL-3 in vitro. Taken together, the present and previous studies of anti-IL-3 mAbs and antisera point to the presence of several neutralizing epitopes that cluster into two regions, surrounded by three epitopes which bind to regions ofIL-3 apparently not immediately involved in receptor interaction.
To confirm the binding site assignments based on the Western blot and immunoprecipitation analyses, many ofthe mAbs were tested in pairs in a sandwich ELISA. As expected, mAbs 6G8 and IF9, which appeared to recognize identical epitopes in the immunoprecipitation analysis, failed to simultaneously bind to human IL-3 in the ELISA (Fig. 7) . Surprisingly, however, although 1F9 bound to human IL-3 in the presence of 3G1 1, 6G8 failed to bind to IL-3 in the presence of 3GI 1. Two conclusions derive from these findings. First, 1F9 and 6G8 must recognize subtly different epitopes within the region between Asp21 and Gln45; and second, the binding epitopes of 6G8 and 3G1 1, which are widely separated in the primary amino acid sequence ofhuman IL-3 (Asp21 to Gin45 and Phe,07 to GluII9, respectively), likely reside in close juxtaposition in the tertiary structure of the molecule. This latter conclusion is quite similar to the findings reported in analyses of GM-CSF, IL-2, and IL-6 (39, (53) (54) (55) . And like the findings reported herein for IL-3, the active receptor binding sites of these cytokines are also composed of amphipathic helixes.
Finally, the ability ofgm 6 to bind to the IL-3 receptor and its near failure to induce signal transduction points to the importance ofthe fourth predicted helix in this latter process. The carboxy-terminal domain may act to induce a proliferative stimulus in responding cells by binding to a signal-transducing region ofthe IL-3 receptor, by causing receptor internalization, by inducing a conformational change in the receptor, or by other mechanisms. Additional studies will be required to determine the precise mechanism ofthis effect. However, the capacity to dissociate receptor binding and signal transduction may find clinical utility as an IL-3 antagonist. The importance of IL-3 in a number ofpathologic processes, including hypersensitivity reactions (4) and leukemogenesis (6, 7) , suggest that alternative therapies based on the principles of rationale drug design may be forthcoming.
